Trial Profile
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer: Big Ten Cancer Research Consortium. BTCRC-LUN17-127
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Plinabulin (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 15 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Jul 2024.
- 13 Oct 2023 Planned End Date changed from 1 Sep 2023 to 1 Jan 2024.
- 19 May 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Sep 2023.